La catena delle opzioni mostra i dati chiave delle opzioni azionarie di MediciNova a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per MediciNova..

MediciNova (NASDAQ:MNOV) Azioni, Catena delle Opzioni

MEDICINOVA INC

MediciNova

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.

MediciNova Inc

D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) with a Buy and maintains $9 price target.

News

Price Target

Analyst Ratings

MNOV

D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target

This significant milestone marks the beginning of a critical trial aimed at providing access to MN-166 for ALS patients who are not eligible for the ongoing Phase 2/3 COMBAT-ALS trial. The EAP trial, funded by the National Institutes of Health (NIH) - Neurological Disorders and Stroke (NINDS)1-3, will evaluate the safety and efficacy of MN-166 in approximately 200 ALS patients.

Reported Earlier, MediciNova Announces First Enrollment In NIH-Supported EAP Trial To Assess MN-166 In Advanced ALS Patients

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the study update and interim analysis results from the Company's COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) will be presented&nbsp;at the 35th International Symposium on ALS/MND held December 6-8, 2024 in Montreal, Canada.
The highlights of the presentation, titled, "COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Interim Analysis Results" (Abstract # 302), include:
<ul>
<li>Study Update: As of November 15, 2024, a total of 217 participants have been enrolled and 183 participants were assigned to either MN-166 or placebo group.</li>
<li>Pre-defined interim analysis was conducted to evaluate the correlation between the 6-month and 12-month data and assess the 12-month double-blind phase trial design.</li>
<li>A subset of patients from the full analysis set who had ALSFRS-R data at 6 months and at least one post-6-month data point. Correlation analysis of the Combined Assessment of Function and Survival (CAFS) scores at 6 and 12 months as well as modified CAFS scores and ALSFRS-R scores were evaluated.</li>
<li>Positive correlations were observed between the 6-month and 12-month data for CAFS score (0.71), modified CAFS score (0.70), and ALSFRS-R (0.69). [Note: Values in parentheses are Spearman Rank Correlation coefficients]</li>
<li>Positive correlations were also observed for Bulbar score (0.74), Fine motor score (0.71), and Gross motor score (0.67), but not for Respiratory score. [Note: Values in parentheses are Spearman Rank Correlation coefficients]</li>
<li>Interim analysis results were reviewed and validated by an external independent Data Safety Monitoring Board (DSMB), which recommended that the trial continue as per the protocol.</li>
</ul>

Biotech

General

MediciNova Presents Study Update And Interim Analysis Of Phase 2/3 Clinical Trial Of MN-166 In ALS At The 35th International Symposium On ALS/MND

WIIM

MediciNova shares are trading higher after D. Boral Capital initiated coverage on the stock with a Buy rating and announced a price target of $9.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>D. Boral Capital analyst Jason Kolbert initiated coverage on MediciNova, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) with a Buy rating and announced a price target of $9. MediciNova shares closed at $2.07 on Friday. See how other analysts view this stock.</li>
<li>Morgan Stanley analyst Patrick Wood initiated coverage on PROCEPT BioRobotics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) with an Overweight rating and announced a price target of $105. PROCEPT BioRobotics shares closed at $95.59 on Friday. <a href="https://www.benzinga.com/quote/PRCT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler analyst Biren Amin initiated coverage on Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with an Overweight rating and announced a price target of $74. Viking Therapeutics shares closed at $52.94 on Friday. <a href="https://www.benzinga.com/quote/VKTX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS analyst Taylor McGinnis initiated coverage on Autodesk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Buy rating and announced a price target of $350. Autodesk shares closed at $291.90 on Friday. <a href="https://www.benzinga.com/quote/ADSK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Daniel Clark initiated coverage on Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with an Outperform rating and announced a price target of $215. Zoetis shares closed at $175.25 on Tuesday. <a href="https://www.benzinga.com/quote/ZTS/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ADSK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="544" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/02085443/image-1-3-1024x544.png" alt="" class="wp-image-672368" style="width:572px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/02085443/image-1-3-1024x544.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/02085443/image-1-3-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/02085443/image-1-3-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/02085443/image-1-3.png 1187w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/12/42265024/how-to-earn-500-a-month-from-marvell-technology-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Marvell Technology Stock Ahead Of Q3 Earnings</a></li>
</ul>

Initiation

Pre-Market Outlook

Markets

Trading Ideas

ADSK

PRCT

VKTX

This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

D. Boral Capital analyst Jason Kolbert initiates coverage on MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) with a Buy rating and announces Price Target of $9.

D. Boral Capital Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $9

To our esteemed stockholders,
Since its founding, MediciNova has been clear in its mission to deliver new treatment options to the patients suffering with unmet medical needs. In service of that mission, we have been steadfast in our commitment to both further our science in partnership with some of the greatest minds across the United States, and to do so in a way that preserves capital and provides optimal value to shareholders.
Our <a href="https://www.globenewswire.com/Tracker?data=5zl89MChTtxXPDuHDITjoRBF1suMt4Cy51p0RlBwDZMlcVgB8_G3_zr8aVLCiaMZNN58nrOChU_v9FRPRPbWJ2xgveiekjkKzNxj1REBPY0nTFK71skA57skl5V5EtH1caYeIss1zwXlFJgTcoUmarj6xEZH00-pwh0-0DBEv-doFSXCXyZFPyBcF1SFGobXTP9bChtnb3IExXSrGeWosO1_Wtmj6FNLkJG_4Jr0Stg=">recently announced</a> collaboration to supply our compound MN166 (ibudilast) as part of an NIH-funded expanded access clinical trial is illustrative of this commitment, as it provides the Company with non-dilutive funding as we collaborate to continue to develop MN166 for ALS without incurring the expenses associated with an additional clinical trial. The six-month trial is being conducted with 17 institutions, all under the aegis of the lead institution and funded entirely by the NIH and without the added expenses of contract research organizations (CROs). Concurrently, we are conducting the COMBAT-ALS trial, our Company-sponsored Phase 2/3 trial of MN166 for ALS, which is a sponsored 12-month trial. We believe that the combination of the two trials allow us to more completely investigate MN166 in a significantly larger patient population, while maintaining a prudent hold on cash.
Importantly, the NIH-funded trial is also very much in line with our corporate strategy, which is to choose a small number of trials on which to focus our resources and identify partners and other funding sources to ensure that additional programs are conducted, our pipeline is robust, and yet our cash reserves are minimally impacted. Another current example of this strategy is an ongoing clinical trial of MN-166 in Long COVID, which is being funded and conducted under the aegis of Health Canada. Much like the ALS program, MediciNova is providing study drug and some administrative support. However, the Canadian government is largely responsible for most other aspects of the trial. Once the trial is complete, Health Canada will turn the results over to the Company at which time it will be in a position to then apply for approval under that indication to Health Canada. We anticipate that there may be advantages in the regulatory process in Canada resulting from the partnership.
We have several additional programs that are being overseen by both U.S. government agencies (NIH, BARDA) and outside the U.S. that follow this model of partnering with prestigious institutions and government agencies to conduct and sponsor clinical trials. Our responsibilities are usually limited to providing study drug in most of these cases, along with administrative and trial design support. Ultimately, for the sake of clarity, we consider our core programs those for which we have direct fiscal responsibility, such as with our COMBAT-ALS trial, as well as the emerging glioblastoma program. However, our non-core programs, such as the above mentioned Long COVID and others for which we only provide study drug and guidance – but almost never cash – are easy ways for us to create revenue over time, and significant shareholder value.
Our cash and cash equivalents position remains strong, with $42.3 million as of September 30, 2024. As discussed, we are extremely careful in the way we use our cash, and we look forward to an additional non-dilutive cash payout as a result of our <a href="https://www.globenewswire.com/Tracker?data=5zl89MChTtxXPDuHDITjoee2szvtytZuzBoDopPxJ5c5dgJIn3Sh1HszrkgMP5hC83-Mz1FlzzJXKCcnMCwq1lhd6X-1NT9rO6Fcy2KJHLRN0m6Nx7MufP1j5iHJZ1w2V96dZ0t5NSc4m77UIjeT7M2wmxoZoK7fdvKb1SM8gZ-Fjnv33nhnV0mJ4yj7VjtEOV6PZoKokWEP9iKrQD23mfmQmy5RSpd94sI9cFEBEHo=">recently announced award</a> in connection with the Sanofi/Novartis settlement. We will provide additional information on that award in the coming weeks.
The global landscape is in a state of perpetual flux, encompassing the natural environment, economy, and technological advancements. In the midst of these dynamic changes, our aspiration is to cultivate a society where every individual can attain lifelong health and enjoy a prosperous and fulfilling life. In pursuit of this vision, we are committed to fostering sustainable growth, and we believe that this approach is essential to manage cash while driving multiple programs through a complicated global development and regulatory landscape.
We also understand that our story may be perceived as complex. I hope that laying out this approach has gone some distance to help clarify our story. In the meantime, we also recently announced that our Chief Business Officer, Dr. David Crean, has also assumed the role of managing our communications. We believe it is essential that current and future investors understand the nuances of our company, and have open, two-way communications to ensure clarity and transparency. Transparency is all the more important as we are the only dual-listed biopharmaceutical company, listed both at NASDAQ market and Tokyo Stock Exchange, which presents the challenge of ensuring that all of our shareholders from both markets are up to date, and in the know.
We are very excited about the future at MediciNova and anticipate providing status updates regularly beginning in the coming weeks. In the meantime, we remain grateful to those shareholders who have shown their loyalty over the years and look forward to welcoming new shareholders to the fold.&nbsp;&nbsp;
Sincerely,
Dr. Yuichi Iwaki
MediciNova Founder, CEO and President

MediciNova Highlights Strategic Focus On Non-Dilutive Funding With NIH-Funded ALS Trial And Canadian Long COVID Study, Reports Strong $42.3M Cash Position, And Reaffirms Commitment To Sustainable Growth And Shareholder Transparency

MediciNova Receives Notice Of Allowance From US PTO For A Pending Patent Application For MN-001 (Tipelukast) To Cover 'Method To Decrease Triglyceride Synthesis In A Liver Of A Subject'

MediciNova shares are trading higher after the company announced that it was notified by Sanofi that the Sanofi/Novartis litigation was settled.

Legal

MediciNova Says Notified By Sanofi That Sanofi/Novartis Litigation Was Settled; Says It Is Entitled To Receive Certain Amount Of Monetary Damages Through This Settlement

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares increased by 27.4% to $3.16 during Thursday's pre-market session. The company's market cap stands at $539.2 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares moved upwards by 24.11% to $0.17. The market value of their outstanding shares is at $5.6 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 21.51% to $0.83. The market value of their outstanding shares is at $79.4 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) stock moved upwards by 19.65% to $2.07. The company's market cap stands at $101.5 million. </li>
<li>Qualigen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) shares increased by 17.24% to $0.2. The market value of their outstanding shares is at $5.5 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock rose 14.78% to $2.95. The company's market cap stands at $23.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares declined by 16.8% to $0.11 during Thursday's pre-market session. The market value of their outstanding shares is at $10.8 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock decreased by 13.59% to $2.29. The company's market cap stands at $5.9 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock declined by 13.56% to $0.35. The market value of their outstanding shares is at $4.8 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock declined by 12.27% to $0.93. The company's market cap stands at $1.8 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares declined by 12.13% to $0.29. The market value of their outstanding shares is at $5.2 million. </li>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock decreased by 9.18% to $0.52. The company's market cap stands at $3.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AZTR

BIVI

CNSP

CYCC

DBVT

ENSC

GNPX

NDRA

Qualigen Therapeutics, Inc. - Common Stock

QLGN

TVGN

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock rose 28.6% to $3.19 during Thursday's pre-market session. The company's market cap stands at $544.3 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares moved upwards by 24.04% to $0.17. The company's market cap stands at $5.6 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 22.17% to $0.83. The company's market cap stands at $79.9 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) shares moved upwards by 19.65% to $2.07. The company's market cap stands at $101.5 million. </li>
<li>Qualigen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) stock rose 14.82% to $0.2. The company's market cap stands at $5.3 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock moved upwards by 14.78% to $2.95. The market value of their outstanding shares is at $23.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares declined by 16.9% to $0.11 during Thursday's pre-market session. The company's market cap stands at $10.8 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares decreased by 13.97% to $2.28. The market value of their outstanding shares is at $5.9 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock fell 13.24% to $0.35. The market value of their outstanding shares is at $4.8 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock declined by 12.27% to $0.93. The market value of their outstanding shares is at $1.8 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares decreased by 12.13% to $0.29. The market value of their outstanding shares is at $5.2 million. </li>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock decreased by 9.18% to $0.52. The company's market cap stands at $3.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Reported Earlier, MediciNova Shares Update Of Phase 2/3 Clinical Trial Of MN-166 (ibudilast) In ALS Patients (COMBAT-ALS) At The 2024 Annual NEALS Meeting

<h3>Gainers</h3>
<ul>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares increased by 51.8% to $0.91 during Friday's regular session. The market value of their outstanding shares is at $9.2 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock rose 22.41% to $0.3. The market value of their outstanding shares is at $7.0 million. </li>
<li>Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) stock rose 21.29% to $1.88. The company's market cap stands at $512.3 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) stock rose 18.15% to $0.47. The company's market cap stands at $1.5 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock moved upwards by 17.99% to $1.64. The market value of their outstanding shares is at $3.0 million. </li>
<li>Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) stock increased by 16.08% to $3.68. The company's market cap stands at $97.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) shares fell 13.4% to $11.47 during Friday's regular session. The market value of their outstanding shares is at $773.3 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares declined by 13.37% to $0.51. The company's market cap stands at $2.2 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock decreased by 10.15% to $6.2. The market value of their outstanding shares is at $80.6 million. </li>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares decreased by 9.95% to $3.53. The company's market cap stands at $3.2 million. </li>
<li>Genenta Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTA#NASDAQ">GNTA</a>) shares declined by 9.69% to $6.25. The company's market cap stands at $113.8 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) shares declined by 9.37% to $1.78. The market value of their outstanding shares is at $87.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CATX

CBUS

ENTO

GNTA

HSCS

NIVF

NUWE

PACB

PTIX

12 Health Care Stocks Moving In Friday's Intraday Session

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the National Institutes of Health (NIH) - Neurological Disorders and Stroke (NINDS) has awarded $22 million for an intermediate size Expanded Access Protocol (EAP) to evaluate the efficacy of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)1,2. In collaboration with an academic group, MediciNova will provide investigational drug MN-166 (ibudilast), regulatory support, and safety monitoring support. &nbsp;
The NIH grant is supported by the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS) signed into law by President Biden. Expanded Access, also referred to as Compassionate Use, is an FDA-regulated pathway that allows individuals with a serious and life-threatening disease to access an investigational drug that is not yet approved by the FDA. This EAP trial will allow individuals with ALS who are not eligible to participate in the COMBAT-ALS trial to receive treatment with MN-166. The EAP will evaluate neurofilament light, a biomarker for neuron damage, and clinical data in two hundred (200) ALS patients treated with MN-166.

Contracts

MediciNova Announces That The National Institutes Of Health Neurological Disorders And Stroke Has Awarded $22M For An Intermediate Size Expanded Access Protocol To Evaluate The Efficacy Of MN-166 In Amyotrophic Lateral Sclerosis

Reported Earlier, MediciNova's MN-166 COMBAT-ALS Trial Abstract Accepted For Poster Presentation At 35th ALS/MND Symposium

Reported Earlier, MediciNova's MN-166 (Ibudilast) ALS Clinical Trial Abstract Accepted For Presentation At 2024 NEALS Annual Meeting

Health Care

Press Releases

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

Comments

MediciNova

MediciNova (MNOV) Opzioni

MediciNova (NASDAQ:MNOV) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO